

Amendments to the claims:

1-12 (canceled)

13. (new) A pteridine derivative selected from the group consisting of:

- 2-amino-4-morpholino-6-(4-acetanilide) pteridine,
- 2-amino-4-morpholino-6-(3-acetanilide) pteridine,
- 2-amino-4-morpholino-6-(4-aminophenyl) pteridine,
- 2-amino-4-morpholino-6-(3-aminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-benzoylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-phenoxyacetylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-propionylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-furoylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-cyclohexanoylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-[4-(4-chlorobenzoyl)aminophenyl] pteridine,
- 2-amino-4-morpholino-6-(4-benzyloxyacetylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(4-isonicotinoylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(4-naphtoylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(4-methylsulfonylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(4-ethylsuccinylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-[4-(4-methylbenzoate)aminophenyl] pteridine;
- 2-amino-4-morpholino-6-(3-benzoylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(3-benzensulfonylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(3-phenoxyacetylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(3-isonicotinoylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(3-cyclohexanoylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-[3-(4-methylbenzoate)aminophenyl] pteridine;

- 2-amino-4-morpholino-6-(3-ethylsuccinylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(3-ethylmalonylaminophenyl) pteridine;
- 2-amino-4-morpholino-6-(3-benzyloxyacetylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-(3-ethylsulfonylaminophenyl) pteridine,
- 2-amino-4-morpholino-6-[3-Boc-(L)-phenylalanine-aminophenyl] pteridine;
- 2-amino-4-morpholino-6-[3-Boc-(D)-phenylalanine-aminophenyl] pteridine;
- 2-amino-4-morpholino-6-[3-Boc-(L)-tryptophane-aminophenyl] pteridine;
- 2-amino-4-morpholino-6-[3-Boc-(D)-tryptophane-aminophenyl] pteridine, and
- 2-amino-4-morpholino-6-(4-hydroxyphenyl) pteridine.

14. (new) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13.

15. (new) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13, and further comprising one or more biologically active drugs selected from the group consisting of immuno-suppressant and/or immunomodulator drugs, antihistamines, antineoplastic drugs and anti-allergic drugs.

16. (new) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13, and further comprising one or more immunosuppressant drugs selected from the group consisting of cyclosporin A; pentoxifylline; daltroban, sirolimus, tacrolimus; rapamycin; leflunomide; mycophenolic acid and salts thereof; azathioprine, brequinar; gusperimus; 6-mercaptopurine; mizoribine; chloroquine; hydroxy-chloroquine; etanercept; infliximab; and kineret.

17. (new) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13 and further comprising one or more immunomodulator drugs selected from the group consisting of acemannan, amiprilose, bucillamine, ditiocarb sodium, imiquimod, Inosine Pranobex, interferon- β , interferon- γ , lentinan, levamisole, pidotimod, romurtide, platonin, procodazole, propagermanium, thymomodulin, thymopentin and ubenimex.

18. (new) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13 and further comprising one or more antineoplastic drugs selected from the group consisting of alkaloids, alkylating agents, alkyl sulfonates, aziridines, ethylenimines, methylmelamines, nitrogen mustards, nitrosoureas, antibiotics, antimetabolites, folic acid analogs, purine analogs, pyrimidine analogs, enzymes, interferon and platinum complexes.

19. (new) A pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13 and further comprising one or more pharmaceutically acceptable carriers or excipients.

20. (new) A method of prevention or treatment of a pathologic condition selected from the group consisting of immune and auto-immune disorders, cardiovascular disorders, disorders of the central nervous system, cell proliferative disorders and allergic conditions, said method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising as an active principle at least one pteridine derivative according to claim 13.

21. (new) A method of prevention or treatment according to claim 20, wherein an effective amount of the pharmaceutical composition corresponds to an amount in the range from 0.01 mg to 20 mg of the pteridine derivative per day and per kg body weight of the patient.

22. (new) A method of prevention or treatment according to claim 20, wherein said pharmaceutical composition further comprises one or more biologically-active drugs selected from the group consisting of immunosuppressant and/or immunomodulator drugs, antihistamines, and anti-allergic drugs, or is administered in combination with an effective amount of a second pharmaceutical composition comprising one or more biologically-active drugs selected from the group consisting of immunosuppressant and/or immunomodulator drugs, antihistamines, and anti-allergic drugs.

23. (new) A method of prevention or treatment according to claim 20, wherein said pharmaceutical composition further comprises one or more immunosuppressant drugs selected from the group consisting of cyclosporin A; pentoxifylline; daltroban, sirolimus, tacrolimus; rapamycin; leflunomide; mycophenolic acid and salts thereof; azathioprine, brequinar; gusperimus; 6-mercaptopurine; mizoribine; chloroquine and hydroxychloroquine.

24. (new) A method of prevention or treatment according to claim 20, wherein said pharmaceutical composition further comprises one or more immunomodulator drugs selected from the group consisting of acemannan, amiprilose, bucillamine, ditiocarb sodium, imiquimod, Inosine Pranobex, interferon- β , interferon- γ , lentinan, levamisole, pidotimod, romurtide, platonin, procodazole, propagermanium, thymomodulin, thymopentin and ubenimex.

25. (new) A method of prevention or treatment according to claim 20, wherein said pharmaceutical composition further comprises one or more antineoplastic drugs selected from the group consisting of alkaloids, alkylating agents, alkyl sulfonates, aziridines, ethylenimines, methylmelamines, nitrogen mustards, nitrosoureas, antibiotics, antimetabolites, folic acid analogs, purine analogs, pyrimidine analogs, enzymes, interferon and platinum complexes.

26. (new) A method of prevention or treatment according to claim 20, wherein said auto-immune disorder is selected from the group consisting of lupus erythematosus, psoriasis, vasculitis, polymyositis, scleroderma, multiple sclerosis, ankylosing spondylitis, rheumatoid arthritis, Sjögren syndrome; auto-immune endocrine disorders, thyroiditis, organ-specific auto-immune diseases, Addison disease, hemolytic or pernicious anemia, Goodpasture syndrome, Graves disease, idiopathic thrombocytopenic purpura, insulin-dependent diabetes mellitus, juvenile diabetes, uveitis, Crohn's disease, ulcerative colitis, pemphigus, atopic dermatitis, autoimmune hepatitis, primary biliary cirrhosis, autoimmune pneumonitis, autoimmune carditis, myasthenia gravis, glomerulonephritis and spontaneous infertility.

27. (new) A method of prevention or treatment according to claim 20, wherein said pathologic condition is an organ or cell transplant rejection.